Publications by authors named "David Cescon"

Claim this Profile
A
A Biomimetic Buffering Hydrogel Scaffold for Long-Term Culture of Patient-Derived Tumor Organoids.
Elizaveta Gusarova, Fatemeh Ahmadi, Jennifer Cruickshank, Zheyuan Miao, David W Cescon

Adv Healthc Mater· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of circulating tumor cell-associated genes in the progression of estrogen receptor-positive breast cancer.
Martin Rotbauer, Melanie Dawe, Kevin C J Nixon, Julissa Tsao, Tanja Durbic, David W Cescon

NPJ Breast Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy.
Hope S Rugo, David W Cescon, Mark E Robson, Seock-Ah Im, Florence Dalenc

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artemis (DCLRE1C) Acts as a Target to Enhance Radiotherapy Response in Triple-Negative Breast Cancer.
Vasudeva Bhat, Kelsie L Thu, Anayra de Fatima Goncalves Santiago, Anna C Bonvissuto, Farhad Ghasemi, David W Cescon

Cancers (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating Treatment Sequencing in Advanced HR+/HER2- Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies.
Dana P Narvaez, David W Cescon

Int J Mol Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine learning-assisted exploration of multidrug-drug administration regimens for organoid arrays.
Ilya Yakavets, Sina Kheiri, Jennifer Cruickshank, Riley J Hickman, Faeze Rakhshani, David W Cescon

Sci Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FAM72A promotes UNG2 degradation and mutagenesis in human cancer cells.
Yuqing Feng, Philip Barbulescu, Chetan K Chana, Melika Shirdarreh, Hong Yang, David Cescon

Sci Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized ctDNA monitoring in metastatic HR+/HER2- breast cancer patients during endocrine and CDK4/6 inhibitor therapy.
Jesús Fuentes-Antrás, Mitchell J Elliott, Sasha C Main, Philippe Echelard, Aaron Dou, David W Cescon

NPJ Breast Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality.
Chelsea E Cunningham, Frederick S Vizeacoumar, Yue Zhang, Liliia Kyrylenko, Simon Both, David W Cescon

Cell Genom· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer.
Mitchell J Elliott, Karen Howarth, Sasha Main, Jesús Fuentes Antrás, Philippe Echelard, David W Cescon

Clin Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.
Peter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy, Massimo Cristofanilli, Stephanie L Graff, David W Cescon

Ther Adv Med Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab and chemotherapy in high-risk, early-stage, ER/HER2 breast cancer: a randomized phase 3 trial.
Fatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, Heather McArthur, Peter Schmid, David W Cescon

Nat Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay.
Mitchell J Elliott, Philippe Echelard, Christodoulos Pipinikas, Sasha Main, Jesús Fuentes Antrás, David W Cescon

Nat Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
Aditya Bardia, Komal Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis, David W Cescon

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microfluidic Platform for Generating and Releasing Patient-Derived Cancer Organoids with Diverse Shapes: Insight into Shape-Dependent Tumor Growth.
Sina Kheiri, Ilya Yakavets, Jennifer Cruickshank, Fatemeh Ahmadi, Hal K Berman, David W Cescon

Adv Mater· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer.
Jeffrey Q Cao, Brae Surgeoner, Mita Manna, Jean-François Boileau, Karen A Gelmon, David W Cescon

Curr Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ionizable Drugs Enable Intracellular Delivery of Co-Formulated siRNA.
Kai V Slaughter, Eric N Donders, Michael S Jones, Sami G Sabbah, Mitchell J Elliott, David W Cescon

Adv Mater· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification.
Christopher Zhang, Benson Z Wu, Caterina Di Ciano-Oliveira, Yin Fang Wu, Sharon S Khavkine Binstock, David W Cescon

Cancer Gene Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting.
Mita Manna, Karen A Gelmon, Jean-François Boileau, Christine Brezden-Masley, Jeffrey Q Cao, David W Cescon

Curr Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC.
Seock-Ah Im, Javier Cortes, David W Cescon, Mastura Md Yusof, Hiroji Iwata

NPJ Breast Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Early-Stage Breast Cancer Survivorship: Evidence-Based Strategies, Surveillance Testing, and Imaging Guidelines.
Mitchell J Elliott, Sherry Shen, Diana L Lam, Thelma Brown, Marissa B Lawson, David W Cescon

Am Soc Clin Oncol Educ Book· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, David W Cescon

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer.
Sierra Pellizzari, Vasudeva Bhat, Harjot Athwal, David W Cescon, Alison L Allan

Radiat Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seize the engine: Emerging cell cycle targets in breast cancer.
Jesús Fuentes-Antrás, Philippe L Bedard, David W Cescon

Clin Transl Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers.
Suzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, David W Cescon, Anna Spreafico

Cancers (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis